MDxHealth SA
No SEC Form 4 filings for $MDXH in the last 30 days.
MDxHealth SA said it will discontinue its Resolve mdx urinary tract infection test and close its Plano, Texas lab, citing reimbursement challenges after Novitas Solutions reversed a Medicare policy, making continued operation “unsustainable,” according to the company. MDxHealth is contesting a $10.4 million recoupment decision. The move lowers 2026 revenue guidance to $110–$115 million from $137–$140 million.
MDxHealth SA director Michael Holder has reported an initial holding of options for 10,000 ordinary shares. The options were granted on June 27, 2025, with an exercise price of $2.18 per share and are set to expire on June 27, 2035. These options will vest in full at the annual general shareholders' meeting held in the calendar year following the grant year.
MDxHealth SA (NASDAQ: MDXH) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. The company will host a conference call and webcast with live Q&A on the same day at 4:30 PM ET to discuss the results and provide a corporate update. MDxHealth is a precision diagnostics company specializing in urologic cancers and diseases.
